Difficulty: Medium
Average Score: 85%
Practice
A 52-year-old woman with end-stage multiple sclerosis who is currently taking several medications including prednisone and neostigmine is seen by a new physician. After examination, the patient has begun on dalfampridine. What is the most likely mechanism of action for this medication?
Correct answer
D
Rationale
The correct answer is D) Potassium channel blocker. Dalfampridine, also known as Ampyra, is a medication used to improve walking in patients with multiple sclerosis by blocking potassium channels. By blocking these channels, dalfampridine helps to enhance nerve conduction in demyelinated axons, improving functional outcomes such as walking speed and endurance in patients with MS.
Option A) Calcium channel blocker: Calcium channel blockers work by blocking calcium channels, which is not the mechanism of action for dalfampridine in this case.
Option B) Cholinesterase inhibitor: Cholinesterase inhibitors are commonly used in conditions like Alzheimer's disease to increase levels of acetylcholine in the brain. This mechanism is not relevant to dalfampridine in multiple sclerosis.
Option C) Permeability enhancer: There is no direct connection between dalfampridine and being a permeability enhancer. It does not act by enhancing cellular permeability.
Educational context: Understanding the mechanism of action of drugs used in the treatment of neurological conditions like multiple sclerosis is crucial for healthcare professionals to make informed decisions about patient care. Knowing how dalfampridine works can help providers explain its benefits to patients and monitor for potential side effects related to its mechanism of action.
Option A) Calcium channel blocker: Calcium channel blockers work by blocking calcium channels, which is not the mechanism of action for dalfampridine in this case.
Option B) Cholinesterase inhibitor: Cholinesterase inhibitors are commonly used in conditions like Alzheimer's disease to increase levels of acetylcholine in the brain. This mechanism is not relevant to dalfampridine in multiple sclerosis.
Option C) Permeability enhancer: There is no direct connection between dalfampridine and being a permeability enhancer. It does not act by enhancing cellular permeability.
Educational context: Understanding the mechanism of action of drugs used in the treatment of neurological conditions like multiple sclerosis is crucial for healthcare professionals to make informed decisions about patient care. Knowing how dalfampridine works can help providers explain its benefits to patients and monitor for potential side effects related to its mechanism of action.